Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 4Lymphoma 2Wilms Tumor 1Plasmacytoma 1Paraproteinemias 1Pancreatic Neoplasms 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Plasma Cell 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1

Interventions

fludarabine phosphate 6Peripheral Blood Stem Cell Transplantation 6Melphalan 6Whole-Body Irradiation 5Tacrolimus 5Mycophenolic Acid 5Dexamethasone 4Cyclophosphamide 4fludarabine 3filanesib 3Bortezomib 3ixazomib 2Steroids 2Sirolimus 2Lenalidomide 2Injections, Subcutaneous 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Etoposide 2Cytarabine 2Carmustine 2Antilymphocyte Serum 2pomalidomide 1merphos 1elotuzumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1carmustine, poliferprosan 20 drug combination 1carfilzomib 1auricularum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Plasma Cell × Proteasome Inhibitors × Clear all
NCT01248923 2020-09-30

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Array BioPharma

Phase 1 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡